Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Capital Leases (2017 - 2023)

Historic Capital Leases for Vistagen Therapeutics (VTGN) over the last 9 years, with Q4 2023 value amounting to $6000.0.

  • Vistagen Therapeutics' Capital Leases fell 2405.06% to $6000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $6000.0, marking a year-over-year decrease of 2405.06%. This contributed to the annual value of $7400.0 for FY2023, which is N/A changed from last year.
  • Vistagen Therapeutics' Capital Leases amounted to $6000.0 in Q4 2023, which was down 2405.06% from $6500.0 recorded in Q3 2023.
  • In the past 5 years, Vistagen Therapeutics' Capital Leases ranged from a high of $8700.0 in Q2 2022 and a low of $300.0 during Q4 2020
  • For the 4-year period, Vistagen Therapeutics' Capital Leases averaged around $5223.1, with its median value being $6000.0 (2023).
  • As far as peak fluctuations go, Vistagen Therapeutics' Capital Leases crashed by 9230.77% in 2020, and later crashed by 1954.02% in 2023.
  • Quarter analysis of 4 years shows Vistagen Therapeutics' Capital Leases stood at $3900.0 in 2019, then crashed by 92.31% to $300.0 in 2020, then soared by 2533.33% to $7900.0 in 2022, then decreased by 24.05% to $6000.0 in 2023.
  • Its Capital Leases stands at $6000.0 for Q4 2023, versus $6500.0 for Q3 2023 and $7000.0 for Q2 2023.